146 related articles for article (PubMed ID: 38420657)
1. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
Mohty M; Bahlis NJ; Nooka AK; DiBonaventura M; Ren J; Conte U
Br J Haematol; 2024 May; 204(5):1801-1810. PubMed ID: 38420657
[TBL] [Abstract][Full Text] [Related]
2. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Costa LJ; LeBlanc TW; Tesch H; Sonneveld P; Kyle RP; Sinyavskaya L; Hlavacek P; Meche A; Ren J; Schepart A; Aydin D; Nador G; DiBonaventura MD
Future Oncol; 2024 Feb; ():. PubMed ID: 38415370
[TBL] [Abstract][Full Text] [Related]
3. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Iida S; Ito S; Yokoyama H; Ishida T; Nagai Y; Handa H; Ito S; Kamei Y; Nakamura M; Suzuki K
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38794892
[TBL] [Abstract][Full Text] [Related]
4. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM; Tomasson MH; Arnulf B; Bahlis NJ; Miles Prince H; Niesvizky R; Rodrίguez-Otero P; Martinez-Lopez J; Koehne G; Touzeau C; Jethava Y; Quach H; Depaus J; Yokoyama H; Gabayan AE; Stevens DA; Nooka AK; Manier S; Raje N; Iida S; Raab MS; Searle E; Leip E; Sullivan ST; Conte U; Elmeliegy M; Czibere A; Viqueira A; Mohty M
Nat Med; 2023 Sep; 29(9):2259-2267. PubMed ID: 37582952
[TBL] [Abstract][Full Text] [Related]
5. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
Moore DC; Granger K; Hill H; Karabinos A; Davis JA
Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
[No Abstract] [Full Text] [Related]
6. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ; Costello CL; Raje NS; Levy MY; Dholaria B; Solh M; Tomasson MH; Damore MA; Jiang S; Basu C; Skoura A; Chan EM; Trudel S; Jakubowiak A; Gasparetto C; Chu MP; Dalovisio A; Sebag M; Lesokhin AM
Nat Med; 2023 Oct; 29(10):2570-2576. PubMed ID: 37783970
[TBL] [Abstract][Full Text] [Related]
7. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Curr Med Res Opin; 2024 Feb; 40(2):199-207. PubMed ID: 38078866
[TBL] [Abstract][Full Text] [Related]
8. Elranatamab: First Approval.
Dhillon S
Drugs; 2023 Nov; 83(17):1621-1627. PubMed ID: 37924427
[TBL] [Abstract][Full Text] [Related]
9. Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma.
Rais T; Khan A; Riaz R
Rare Tumors; 2023; 15():20363613231207483. PubMed ID: 37840703
[TBL] [Abstract][Full Text] [Related]
10. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Leuk Lymphoma; 2024 May; 65(5):660-668. PubMed ID: 38347747
[TBL] [Abstract][Full Text] [Related]
11. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
Mutlu YG; Yıgıt Kaya S; Maral S; Melek E; Baslar Z; Kaynar L; Sevindik OG
Front Immunol; 2023; 14():1276295. PubMed ID: 37901215
[TBL] [Abstract][Full Text] [Related]
12. Elranatamab: a new promising BispAb in multiple myeloma treatment.
Grosicki S; Bednarczyk M; Kociszewska K
Expert Rev Anticancer Ther; 2023; 23(8):775-782. PubMed ID: 37434334
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
15. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
16. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
17. Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis.
Van de Wyngaert Z; Romera-Martinez I; Chedeville C; Musiu P; Ikhlef S; Jonca B; Mohty M; Malard F
Clin Hematol Int; 2024; 6(2):46-50. PubMed ID: 38817306
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
Jourdes A; Cellerin E; Touzeau C; Harel S; Denis B; Escure G; Faure E; Jamard S; Danion F; Sonntag C; Ader F; Karlin L; Soueges S; Cazelles C; de La Porte des Vaux C; Frenzel L; Lanternier F; Brousse X; Cazaubiel T; Berger P; Collignon A; Blot M; Pieragostini A; Charles M; Chaleteix C; Redor A; Roland V; Cartau T; Macro M; Chalopin T; Vallet N; Perrot A; Martin-Blondel G;
Clin Microbiol Infect; 2024 Jun; 30(6):764-771. PubMed ID: 38432433
[TBL] [Abstract][Full Text] [Related]
19. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma.
Kamal M; Wang XS; Shi Q; Zyczynski TM; Davis C; Williams LA; Lin HK; Garcia-Gonzalez A; Cleeland CS; Orlowski R
Support Care Cancer; 2021 Jan; 29(1):467-475. PubMed ID: 32390093
[TBL] [Abstract][Full Text] [Related]
20. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
